"Elan slips despite boost from Brussels": "Elan slips despite boost from Brussels
"ELAN was one of the few losers on the Dublin market yesterday as most shares piled on new gains.The drug company saw its market price drop 52c to 1273, despite getting approval from the EU to launch its multiple sclerosis drug Tysabri on the European market.'I think people were expecting the approval to come through, which is why it didn't make a dramatic impact,' explained analyst Ian Hunter of Goodbody Stockbrokers.'Also, now that it is through, people are beginning to realise that other elements such as its pricing in Europe and its rollout in the U.S. are still to come,' he added..............."